Moreover, ARV-825 treatment produces a more pronounced effect on the inhibition of c-Myc than that of the BRD4 inhibitors in five MM cell lines [SKO-007(J3), U266, RPMI-8226, ARP-1, JJN3] and an MM patient-derived CD138+ MM cells (192). The gene discussed is MYC; the disease is Miyoshi myopathy.